---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-25-000446"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:48:19.786442+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M

## Summary
- Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.
- Positive Q4 operating cash flow of $4.2M; SG&A down 12% YoY.
- Added six new value-based contracts in H2 2024 covering over 250k lives; dispensary revenue at record.
- 2025 guidance: revenue $420-$450M, adjusted EBITDA loss $19-$24M, improved free cash flow.
- New drug-supplier agreement expected to improve discounts and cost positioning.

## SEC filing metadata
- accession: 0001079973-25-000446
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000107997325000446/0001079973-25-000446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000107997325000446/toi_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-25-000446
- JSON: https://secwatch.observer/filing/0001079973-25-000446.json
- Plain text: https://secwatch.observer/filing/0001079973-25-000446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.